| Literature DB >> 36207046 |
Blossom Lake1,2, Sarah Damery2, Kate Jolly2.
Abstract
BACKGROUND: Elevated body mass index (BMI) in breast cancer survivors (BCS) is associated with cancer recurrence and poorer treatment response. Guidelines recommend 5%-10% weight loss for overweight or obese BCS.Entities:
Keywords: breast tumours; clinical physiology; nutrition & dietetics
Mesh:
Year: 2022 PMID: 36207046 PMCID: PMC9557263 DOI: 10.1136/bmjopen-2022-062288
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Flow diagram.
Characteristics of included reviews
| Study, country | Review type, no. databases searched, restrictions | Study design(s), (number of studies included) | Number of participants, breast cancer treatment status | Intervention, control | Follow-up length |
| Bekhet | Systematic review | RCTs (n=12) | 1120 | Aerobic exercise, supervised or home-based | 10 weeks to 12 months |
| Boing | Systematic review and meta-analysis | RCTs (n=5) | 368 | Aerobic training alone (n=1) | 8–48 weeks |
| Chlebowski and Reeves | Systematic review | RCTs (n=8) | 1325 | 12 weeks to 24 months | |
| Guinan | Systematic review | RCTs (n=7) | 435 | Aerobic exercise alone or combined with resistance training (n=7) | 8 weeks to 6 months |
| Ingram | Systematic review | RCTs (n=9) | 725 | Aerobic exercise (n=7) | 6–26 weeks |
| Lahart | Systematic review and meta-analysis | RCTs (n=60) | 5761 | Aerobic exercise only (n=28) | 4–24 months |
| Lee and Lee | Systematic review and meta-analysis | RCTs (n=29) | 2989 | Aerobic and resistance exercise (n=17) | 4 weeks to 12 months |
| Lopez | Systematic review and meta-regression | RCTs (n=8) | 985 | Combined resistance and aerobic training (n=9) | 4 weeks to 6 months |
| McNeely | Systematic review and meta-analysis | RCTs (n=14) | 717 | Mixed aerobic and resistance exercise | 7 weeks to 6 months |
| Pan | Systematic review and meta-analysis | RCTs (n=9) | 322 | Tai Chi Chuan | 10 weeks to 6 months |
| Playdon | Systematic review | RCTs (n=8), cohort intervention studies (n=4), randomised parallel interventions (n=2), non-RCTs (n=1), | 1028 | Weight loss intervention (any combination of diet, physical activity and/or behavioural components with a focus on weight loss) | 8 weeks to 12 months |
| Reeves | Systematic review | RCTs (n=10) | 654 | RCTs: diet and PA (n=6), diet alone (n=4) | 6–12 months |
| Shaikh | Systematic review and meta-analysis | RCTs (n=17), randomised crossover trials (n=3) | 2028 | Diet interventions only (n=3) | 2 weeks to 24 months |
| Singh | Systematic review and meta-analysis | RCTs (n=61) | 5200 | Aerobic exercise only (n=20) | 6 weeks to 12 months |
| Soares Falcetta | Systematic review and meta-analysis | RCTs (n=60) | 6303 | PA interventions (with or without dietary intervention) | 4 weeks to 24 months |
| Thomson and Reeves | Systematic review | RCTs (n=5) | 381 | Behavioural-based dietary intervention±PA and weight gain prevention | 6–12 months |
| Wang | Systematic review and meta-analysis | RCTs (n=11) | 666 | PA interventions (aerobic, flexible/endurance exercise, resistance training, yoga, stretching, dancing) | 8–24 weeks |
PA, Physical activity; RCT, randomised controlled trial.
Proportion of studies shared by pairs of reviews
| Bekhet | Boing | Chlebowski | Guinan | Ingram | Lahart | Lee | Lopez | McNeely | Pan | Playdon | Reeves | Shaikh | Singh | Soares-Falcetta | Thomson | Wang | |
| Bekhet | 7 | 0 | 0 | 4.8 | 0 | 4.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.4 | 3.5 | 0 | 0 |
| Boing | 14 | 7 | 0 | 0 | 0 | 2.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.5 | 0 | 0 |
| Chlebowski | 15 | 15 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.1 | 0 | 10.3 | 0 | 0 |
| Guinan | 21 | 21 | 22 | 14 | 4.0 | 7.3 | 0 | 0 | 9.5 | 0 | 0 | 0 | 0 | 4.5 | 9.4 | 0 | 0 |
| Ingram | 18 | 18 | 19 | 25 | 11 | 1.9 | 0 | 5.0 | 11.1 | 0 | 0 | 0 | 0 | 1.6 | 16.3 | 0 | 0 |
| Lahart | 48 | 48 | 49 | 55 | 52 | 41 | 1.9 | 0 | 6.3 | 2.1 | 0 | 0 | 0 | 11.8 | 13.2 | 0 | 0 |
| Lee | 20 | 20 | 21 | 27 | 24 | 54 | 13 | 9.5 | 0 | 0 | 0 | 0 | 0 | 7.7 | 1.6 | 0 | 0 |
| Lopez | 16 | 16 | 17 | 23 | 20 | 50 | 21 | 9 | 0 | 0 | 0 | 0 | 0 | 1.6 | 0 | 0 | 0 |
| McNeely | 14 | 14 | 15 | 21 | 18 | 48 | 20 | 16 | 7 | 0 | 0 | 0 | 0 | 1.7 | 5.3 | 0 | 0 |
| Pan | 14 | 14 | 15 | 21 | 18 | 48 | 20 | 16 | 14 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Playdon | 21 | 21 | 22 | 28 | 25 | 55 | 27 | 23 | 21 | 21 | 14 | 32.1 | 10.8 | 0 | 1.6 | 0 | 0 |
| Reeves | 21 | 21 | 22 | 28 | 25 | 55 | 27 | 23 | 21 | 21 | 28 | 14 | 13.5 | 0 | 4.7 | 0 | 0 |
| Shaikh | 30 | 30 | 31 | 37 | 34 | 64 | 36 | 32 | 30 | 30 | 37 | 37 | 23 | 0 | 12.3 | 0 | 0 |
| Singh | 59 | 59 | 60 | 66 | 63 | 93 | 65 | 61 | 59 | 59 | 66 | 66 | 75 | 52 | 6.9 | 0 | 0 |
| Soares-Falcetta | 57 | 57 | 58 | 64 | 61 | 91 | 63 | 59 | 57 | 57 | 64 | 64 | 73 | 102 | 50 | 0 | 1.9 |
| Thomson | 12 | 12 | 13 | 19 | 16 | 46 | 18 | 14 | 12 | 12 | 19 | 19 | 28 | 57 | 55 | 5 | 0 |
| Wang | 11 | 11 | 12 | 17 | 15 | 45 | 17 | 13 | 11 | 11 | 18 | 18 | 27 | 56 | 54 | 9 | 4 |
Grey cells indicate the number of primary studies in a given review that reported one or more of our outcomes of interest. White cells show the total number of primary studies in each pair of reviews which reported one or more of our outcomes of interest. In the upper right section of table 2, numbers indicate the proportion of primary studies in each pair of reviews that were the same (green cells indicate overlap <5%; yellow cells indicate overlap between 5% and <10%; pink cells show overlap of 10%–<15% and dark red cells indicate overlaps of 15% or greater).